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REVIEW
Multi-morbidities of allergic rhinitis 
in adults: European Academy of Allergy 
and Clinical Immunology Task Force Report
C. Cingi1*, P. Gevaert2, R. Mösges3, C. Rondon4, V. Hox5, M. Rudenko6, N. B. Muluk7, G. Scadding8, F. Manole9, 
C. Hupin10, W. J. Fokkens11, C. Akdis12, C. Bachert2, P. Demoly13, J. Mullol14, A. Muraro15, N. Papadopoulos16, 
R. Pawankar17, P. Rombaux18, E. Toskala19, L. Kalogjera20, E. Prokopakis21, P. W. Hellings5 and J. Bousquet13
Abstract 
This report has been prepared by the European Academy of Allergy and Clinical Immunology Task Force on Allergic 
Rhinitis (AR) comorbidities. The aim of this multidisciplinary European consensus document is to highlight the role of 
multimorbidities in the definition, classification, mechanisms, recommendations for diagnosis and treatment of AR, 
and to define the needs in this neglected area by a literature review. AR is a systemic allergic disease and is generally 
associated with numerous multi-morbid disorders, including asthma, eczema, food allergies, eosinophilic oesophagi-
tis (EoE), conjunctivitis, chronic middle ear effusions, rhinosinusitis, adenoid hypertrophy, olfaction disorders, obstruc-
tive sleep apnea, disordered sleep and consequent behavioural and educational effects. This report provides up-to-
date usable information to: (1) improve the knowledge and skills of allergists, so as to ultimately improve the overall 
quality of patient care; (2) to increase interest in this area; and (3) to present a unique contribution to the field of 
upper inflammatory disease.
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Olfaction disorders, Rhinitis, Rhinosinusitis
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Introduction
This report was prepared by the European Academy of 
Allergy and Clinical Immunology (EAACI) Task Force on 
“Allergic Rhinitis (AR) comorbidities”. This was initiated, 
based on the rationale that AR is rarely found in isolation 
and needs to be considered in the context of systemic 
allergic disease associated with numerous comorbid dis-
orders including asthma, chronic middle ear effusions, 
sinusitis, lymphoid hypertrophy with obstructive sleep 
apnea, disordered sleep, and consequent behavioural and 
educational effects.
AR, which has increased in prevalence over several 
decades, now affects 10–30% of the population, with the 
greatest frequency found in children and adolescents [1]. 
It typically presents after the second year of life but the 
exact prevalence in early life is unknown. Since children’s 
immune systems develop between the first and fourth 
years of life, those with an atopic predisposition begin to 
express allergic disease with a clear  Th2 response to aller-
gen exposure, resulting in symptoms, often beginning 
with atopic dermatitis (AD) and progressing to asthma 
and rhinitis (the allergic march) [1]. However after early 
childhood, AR is usually the initial manifestation of 
allergy [2].
AR is associated with numerous multi-morbid disor-
ders. Those occurring in children have already been dis-
cussed in the EAACI Task Force on Paediatric Rhinitis 
[3]. This paper, by contrast, concerns itself largely with 
adult AR multimorbidities, but includes relevant paedi-
atric data.
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Definition
Multimorbidity is the presence of one or more addi-
tional disorders (or diseases) co-occurring with a primary 
disease or disorder; or the effect of such additional dis-
orders or diseases [4]. When the primary organ is not 
known, the term multimorbidity should be used instead 
of co-morbidity. In allergic diseases, the term should be 
multimorbidity.
Multi‑morbidities of allergic rhinitis
AR is an organ-specific manifestation of allergic disease. 
As such, it coexists with other organ-specific disorders 
that have a common allergic basis. It is therefore rarely 
found in isolation but frequently has associated multi-
morbid disorders [5].
These can be subdivided into:
(a) Disorders which are part of the spectrum of aller-
gic diseases, e.g. asthma, AD, food allergy, anaphy-
laxis;
(b) Disorders anatomically related to the nose: con-
junctivitis, sinusitis, middle ear problems, throat 
and laryngeal effects;
(c) Sleep problems and secondary effects on concen-
tration and behaviour; and
(d) Turbinate hypertrophy.
Although more common in paediatric practice, the 
occurrence of multi-morbidities in adults is significant 
and has important implications for quality of life, and 
work attendance and performance. It is likely that those 
with severe chronic upper airways disease (SCUAD) suf-
fer more severe co-morbid effects.
Asthma
Extent of co‑occurrence
A European study of over 20,000 children showed that 
the co-existence of eczema, asthma and rhinitis in the 
same child is more frequent than expected if they were 
independent entities. Those children with one of these 
diseases at age 4 were 4–7 times more likely to have two 
or three of them at age 8. Children with two or three 
allergic diseases at 4 years are 30–60 times more likely to 
have two or three of these diseases at age 8 [6].
The association between asthma and rhinitis in adults 
has been recognized for some decades, since the pioneer-
ing study of Brydon [7], who showed that the majority of 
1000 asthmatics also had rhinitis, which preceded their 
asthma in 45% of the subjects.
In fact the majority of inflammatory asthma sufferers 
have some form of upper airway disease (ARIA 2001) 
[8], either AR, non-allergic rhinitis or rhinosinusitis, usu-
ally with nasal polyposis (EPOS 2012) [9]. The extent of 
inflammation is usually proportional between upper and 
lower respiratory tracts with equivalence in eosinophils 
[10] and clinical severity [11].
Several possible relations exist between AR and asthma: 
(a) AR may be statistically associated with asthma; (b) AR 
may exacerbate coexisting asthma; and (c) AR may have a 
causal role in the pathogenesis of asthma.
Several possible causal mechanisms have been postu-
lated to explain a link between AR and asthma:
  • Lack of nasal function, i.e. purifying, warming and 
humidifying inspired air;
  • Nasobronchial reflex (nasal irritants, allergens or 
cold stimuli);
  • Rhinovirus adhesion theory (increased susceptibility 
to allergic inflammation and intracellular adhesion 
molecule (ICAM)-1 expression) [12]; and
  • “Migration” of T cell responses to other tissues after 
initial sensitization. Braunstahl [13] has shown that 
allergen challenge in one part of the airway is fol-
lowed by a response in all other parts;
  • The idea of postnasal drip (carriage of inflammatory 
cytokines/mediators from nasopharynx to lower 
airways) has been largely abandoned, since the ‘drip’ 
travels to the gut, by virtue of the larynx, not to the 
lower airway, unless the subject is deeply uncon-
scious.
Certainly the presence of rhinitis, both allergic and 
non-allergic, is a risk factor for subsequent asthma devel-
opment [14].
Effects of co‑occurrence
The co-existence of rhinitis is associated with poor 
asthma control in adults, adolescents and children 
[15]. Recent studies on AR and asthma are presented in 
Table 1 [16–19].
Atopic dermatitis (AD)
Extent of co‑occurrence
In children, there are clear data concerning the co-occur-
rence of AD and AR, largely from birth cohorts [20].
In one Taiwanese study [21], AR was the most com-
mon concomitant atopic disease associated with AD. The 
group with AD and AR was shown to be more likely to 
have serum mite-, cockroach- and feather-specific IgE, 
whereas the positive rates for wheat, peanut and soybean 
were higher in those with AD without rhinitis.
In a Croatian study [22], the age at onset was younger 
in the group of AD patients with concomitant AR, sug-
gesting that AD multi-morbidity (although part of the 
allergic march) may be irrelevant to the later develop-
ment of isolated respiratory allergy.
Page 3 of 12Cingi et al. Clin Transl Allergy  (2017) 7:17 
Taken together these observations suggest that sensi-
tization in later onset allergy is not via the skin, but by 
inhalant allergens acting via the respiratory tract mucosa 
[2].
Effects of co‑occurrence
While some data suggest that the greater extent of aller-
gic disease promotes more severe reactions [23, 24], 
other researchers note an inverse relationship between 
exacerbations in skin and in the respiratory tract [25].
In patients with asthma, AD and AR, the risks of sys-
temic glucocorticoid bioavailability are highest, since 
treatment is likely to be directed to three sites: skin, bron-
chi and nose. Absorption occurs (from least to greatest 
rate) in the nasal mucosa, followed by the bronchi, then 
the skin. Alternative means of treatment (such as allergen 
avoidance, saline douching, antihistamines, anti-leukot-
rienes, immunotherapy and anti-cytokines) may need to 
be considered.
Food allergy
Extent of co‑occurrence
AR can be associated with primary food allergy; how-
ever, it is more frequently associated with secondary 
food allergy, also known as pollen food syndrome (PFS). 
Some medical professionals refer to pollen food syn-
drome as oral allergy syndrome (OAS), although strictly 
speaking the two are not the same. When the term OAS 
was first used in 1987 it had no connection with pol-
len allergy but referred to any allergic symptoms in the 
mouth that often preceded more serious symptoms. The 
term pollen food syndrome is preferred when referring 
to those allergy symptoms to food that are linked to pol-
len allergy, are limited to the mouth and throat, and are 
usually mild. [26]. The most typical example is the cross-
reactivity in patients with birch pollen AR who develop 
oral symptoms when eating apples, hazelnut, celery, 
etc. Typically, when these foods are cooked or pro-
cessed they can be eaten without causing allergic reac-
tions. Allergic reactions in secondary allergy are usually 
less severe than in primary food allergy [27]. Common 
symptoms, which usually come on immediately, include: 
redness, mild swelling or itching of the lips, tongue, 
inside of the mouth, soft palate and ears, itching and 
mild swelling affecting the throat. Occasionally, peo-
ple might also experience symptoms in the oesophagus 
(gullet) or stomach, causing abdominal pain, nausea and 
even vomiting. Sneezing, runny nose, or eye symptoms 
can also occur.
Those sensitised to both birch and grass pollens are 
more likely to develop pollen food syndrome [28, 29]. 
They may also experience symptoms to a wider range of 
fresh fruits and raw vegetables than those who are sensi-
tised to birch pollen alone.
Table 1 Asthma and AR
References Study type No. patients Age/Profile Aim of the study Results
Ciprandi 
et al. [16]
Prospective 89 (AR), 940 
(controls)
Adults Follow up of patients with 
AR every 2 years for 8 years 
to investigate spirometric 
abnormalities/BHR
34 of 89 AR patients developed BHR after 
8 years
Sensitization to mite, birch and parietaria, 
as well as rhinitis duration are risk factors
Navarro 
et al. [17]
Epidemiologic pro-
spective; multi centre
942 (with 
asthma)
Mean age: 35.5; 
63% female
Investigate the link between 
the upper and lower 
airways
89.5% had AR
Correlation between severity of rhinitis 
and asthma (p < 0001) and inverse 
correlation with age (p < 0.0001) and 
severity of asthma (p < 0.05)
Ko et al. [18] Cross sectional; ques-
tionnaire
600 (with 
asthma)
267 male; 333 
female
Evaluation of prevalence of 
AR in asthma
77% of asthmatics had rhinitis in the past 
12 months (of whom 96% were previ-
ously diagnosed with AR)
In patients with asthma and rhinitis, 49% 
use nasal steroids, resulting in fewer ED 
visits (13 vs 25%) and fewer hospitaliza-
tions for asthma (5 vs 13%)
Valero et al. 
[19]
Cross-sectional inter-
national population 
study; based on 
questionnaire
3225; 1 posi-
tive skin test
Age range: 10–50; 
53% male
Evaluation of the link 
between AR, asthma and 
skin test sensitization
Asthma presents in 49% of AR patients
Asthma severity was associated with 
length of time from onset and with 
allergic rhinitis severity
Patients with asthma have a higher 
number of allergen sensitizations and 
higher sensitization intensity than those 
without asthma (p < 0.01)
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In one Italian study of pollen sensitive AR subjects 
aged 4–18  years old, a longer AR duration was signifi-
cantly associated with moderate-to-severe AR symptoms 
(p =  0.004), and with co-morbidities such as asthma (p 
0.030), PFS was present in 24% (p < 0.001) [30]. In a study 
of 110 UK adults with spring hay fever, 52 participants 
(47%) were diagnosed with PFS, which is the commonest 
form of food allergy in the UK [29].
Interestingly, birth order effects differ for different 
allergic disorders in a large Japanese study of 14,669 
schoolchildren aged 7–15  years [31]. There was no sig-
nificant difference in the prevalence of BA or AD accord-
ing to birth order, whereas the prevalence of AR, allergic 
conjunctivitis and FA decreased significantly as birth 
order increased. This raises questions about the effects of 
hygiene on different allergic manifestations.
Treatment
PFS is usually a mild type of food allergy that occurs 
upon contact of the mouth and throat with raw fruits or 
vegetables containing epitopes also present in a pollen to 
which the subject is sensitized [32].
PFS is a problem in patients sensitized to various pol-
len allergens. There was clear association between PFS 
and polyvalent airborne allergy (69%). Cross-reactivity 
patterns were typical (for example, tree pollen allergy—
intolerance of apples, carrots and potatoes; grass pollen 
allergy—intolerance of kiwi fruit and tomatoes). Subcuta-
neous SIT significantly alleviated PFS symptoms associ-
ated with ingestion of the responsible fruit and vegetables 
in patients [33].
The treatment is avoidance of the food(s) causing 
reaction(s). Adrenalin is only indicated if severe reac-
tions are described in the medical history, or if there are 
reactions to processed food. For primary food allergy an 
experimental study of SIT using peanuts was suspended 
because of adverse reactions [34].
SIT for food allergy is reaching the point where it may 
soon be used routinely in clinical practice. Sublingual 
immunotherapy is effective for desensitization with a very 
favorable adverse event profile. Epicutaneous immuno-
therapy is also effective, most notably in younger children, 
with a high rate of local reactions. Oral immunotherapy 
demonstrates high efficacy, but with a higher risk of gas-
trointestinal and systemic adverse events. The need for 
long-term application to sustain desensitization is cur-
rently unclear. Immunomodulatory adjuvants may be 
added to enhance or diminish the immunogenicity of pro-
teins, whereas genetic modifications of food allergens are 
designed to limit the risk of adverse reactions and address 
the issues of standardization and supply [35].
The most common pollen-fruit cross-reaction is the 
birch-apple syndrome [36]. Mauro et al. [36] investigated 
patients with birch-apple syndrome to evaluate the out-
come of subcutaneous immunotherapy (SCIT) and sub-
lingual immunotherapy (SLIT). Two of 8 SCIT-treated 
patients (25%) and 1 of 7 SLIT-treated patients (14.2%) 
developed complete tolerance to apple. In the remain-
ing patients, an increase in the provocative dose was 
found in 3 of the SCIT-treated (37.5%) and 2 of the SLIT-
treated patients (28.6%). They concluded that different 
doses of birch extract may be needed in different patients 
to improve the associated apple allergy and that a finer 
diagnostic work-up in selecting patients with birch-apple 
syndrome who are candidates to respond to birch pollen 
IT also concerning apple allergy is required [36].
Eosinophilic oesophagitis (EoE)
Description
EoE is currently defined as a “chronic, immune/antigen-
mediated esophageal disease characterized clinically by 
symptoms related to esophageal dysfunction and histo-
logically by eosinophil-predominant inflammation” [37].
EoE is a clinicopathologic disorder diagnosed by clini-
cians taking into consideration both clinical and patho-
logic information:
  • Symptoms related to esophageal dysfunction;
  • Eosinophil-predominant inflammation on esopha-
geal biopsy, which is required for diagnosis, charac-
teristically consisting of a peak value of ≥15 eos per 
high power field (eos/hpf ) [38];
  • Response to treatment (dietary elimination; topical 
corticosteroids) supports, but it is not required, for 
diagnosis (Strong recommendation, low evidence) 
[37].
Extent of co‑occurrence
EoE is commonly associated with other atopic diatheses 
(e.g. food allergy, asthma, eczema, chronic rhinitis, envi-
ronmental allergies) [39]. In adults, solid food dysphagia 
is the most common presenting symptom [40, 41], with 
food impaction necessitating endoscopic bolus removal 
occurs in 33–54% of adult EoE patients [42]. Other symp-
toms in adults include chest pain, heartburn and upper 
abdominal pain [38, 43].
Treatment
  • Acid suppression Approximately one-third of patients 
with suspected eosinophilic esophagitis have a good 
clinical and histologic response to proton pump 
inhibitors (PPIs alone, suggesting that GERD, or a 
PPI-responsive form of esophageal eosinophilia, may 
be responsible [44, 45].
  • Dietary therapy is an effective treatment for eosino-
philic esophagitis in children and adults. Dietary 
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therapy is based upon the observation that patients 
with eosinophilic esophagitis have high rates of food 
allergies, and that those allergies may contribute to 
the development of eosinophilic esophagitis [44].
Topical corticosteroids have been proven to be an effec-
tive therapy for EoE and are a first-line therapy. Whilst 
available as multi-dose inhalers or aqueous nebulizer 
solutions for use in asthma, to treat EoE the medication 
is swallowed rather than inhaled to coat the esophagus 
and provide topical medication delivery (Recommenda-
tion strong, evidence high) [38].
Oral prednisone (a synthetic corticosteroid drug) may 
be useful to treat EoE if topical steroids are not effective 
or in patients who require rapid improvement in symp-
toms (Recommendation conditional, evidence low) [38].
Patients without symptomatic and histologic improve-
ment after topical steroids might benefit from a longer 
course of topical steroids, higher doses of topical ster-
oids, systemic steroids, an elimination diet or esophageal 
dilatation (Recommendation conditional, evidence low) 
[38].
  • Esophageal dilation Dilation of esophageal strictures 
is effective for relieving dysphagia, but has no effect 
on underlying inflammation [46, 47].
  • Other experimental treatments Prostaglandin 
D2 receptor antagonist [48], leukotriene inhibi-
tors (Montelukast) [49], Mepolizumab: humanized 
monoclonal antibody against interleukin (IL)-5 [50], 
purine analogues (Azathioprine or 6-mercaptopu-
rine) [44, 51].
Allergic conjunctivitis
Extent of co‑occurrence
Allergic conjunctivitis is the typical conjunctival reaction 
in AR. It occurs following exposure to allergens. Ocu-
lar symptoms occur in 50–70% of patients with rhini-
tis, being more common with outdoor than with indoor 
allergens [52]. Pitt et al. [53] reported that seasonal aller-
gic conjunctivitis (SAC) is associated with significant 
reductions in both ocular and general quality of life.
Effects of co‑occurrence
Eye symptoms include itching, watering, redness and 
difficulty with vision due to these. Ocular symptoms are 
reduced by nasal air filters [54], suggesting that some eye 
involvement is secondary to nasal reflexes.
Treatment
Some INS reduce eye symptoms as well as nasal ones, the 
recent molecules appear more consistently effective [55]. 
The combination of intranasal antihistamine plus INS 
shows greater efficacy on rhinoconjunctivitis [56]. The 
topical ocular antihistamines, antazoline, azelastine, and 
emedastine, provide rapid relief of the symptoms of aller-
gic conjunctivitis [57].
Rhinosinusitis
Extent of co‑occurrence
The extent of co-occurrence of rhinosinusitis is dis-
puted and is likely to be different in acute rhinosinusitis 
(ARS), chronic rhinosinusitis (CRS) and CRS with nasal 
polyposis.
Effects of co‑occurrence
When considering the role of allergy in sinus disease, it 
can be speculated that nasal inflammation induced by 
IgE-mediated mechanisms favours the development of 
acute and/or chronic sinus disease [58, 59].
Several mechanisms could explain the link between 
allergic inflammation and sinus disease. Allergic inflam-
mation of the nasal mucosa may give rise to mucosal 
congestion leading to impaired mucus drainage at the 
ostiomeatal complex in predisposed patients. Osti-
omeatal pathology is considered to be essential to the 
generation of sinus-related symptoms [59].
Certainly, AR sufferers experience common colds 
(which are a form of acute rhinosinusitis) more severely 
and for longer than those without underlying minimal 
persistent inflammation [11]. The contribution of AR to 
chronic rhinosinusitis is less clear (EPOS 2012) [9]. One 
study has demonstrated that, in children, the degree of 
atopy (as reflected by the number of aeroallergen sensi-
tivities or the presence of atopic multi-morbidities) is not 
associated with progression to CRS in the pediatric age 
group [60].
Symptoms of IgE-mediated allergic inflammation 
should be asked for during history taking in patients with 
CRS and specific allergy evaluation should be performed 
in case of clinical suspicion. With regard to treatment, it 
is recommended that anti-allergic therapy is added to the 
treatment of patients with chronic sinus disease and con-
comitant allergy [61].
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Chronic rhinosinusitis with nasal polyps (CRSwNP) is 
associated with high concentrations of IgE in nasal polyp 
(NP) tissue. CRSwNP often coexists with asthma and this 
group is particularly characterized with tissue eosino-
philia and high local IgE levels [62]. Therefore, an allergic 
aetiology of NPs has been presumed, though never firmly 
demonstrated. Between 0.5 and 4.5% of subjects with 
AR have NPs, which compares with the normal popula-
tion [9]. In a retrospective study by Settipane and Cha-
fee [63], the nasal polyps were present in 4.2% of the total 
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population of 4986 subjects. Nasal polyp frequency rate 
was 6.7% in asthmatic patients and 2.2% in the rhinitis 
alone group. Of the total 211 cases of nasal polyps, 71% 
had asthma and 29% had rhinitis alone [63]. Pang et  al. 
[64] reported that food allergen intradermal tests were 
more positive in nasal polyp patients (81%) compared to 
controls (11%).
In mucosal tissues, mRNA for the ε-chain of IgE was 
associated with a significant proportion of B cells [65, 
66]. Recent evidence has shown local IgE synthesis, local 
receptor revision, class switch recombination and B-cell 
differentiation into IgE-secreting plasma cells in NPs [64]. 
In NPs, the level of IgE is independent of the atopic sta-
tus of the patient [65, 67, 68] whereas specific IgE in NPs 
is only partly related to skin prick test positivity [65, 67, 
68]. The local IgE in NPs is the result of two types of IgE 
production: systemic allergic IgE formation and a local 
polyclonal IgE formation [65, 66]. Local polyclonal IgE 
correlates with the presence of Staphylococcus aureus 
enterotoxins (SAE) [9, 65–67]. Finally, Gevaert et  al. 
[69] demonstrated that antagonizing IgE by injections of 
omalizumab is effective for both allergic and nonallergic 
CRSwNP. The later finding proves the relevance of local 
mucosal IgE.
CRSwNP is an IgE mediated disease; however, the role 
of atopy is less clear.
Otitis media with effusion (OME)
Extent of co‑occurrence
In one hospital population of children with chronic 
OME, over 80% had rhinitis [70]. A population survey in 
Slough schools (in the UK) also demonstrated an associa-
tion between OME type symptoms and rhinitis [71].
OME is much rarer in adults and is usually found in 
association with more severe rhinosinusitis (such as aspi-
rin exacerbated respiratory disease, allergic fungal sinusitis 
and Churg Strauss syndrome) rather than with rhinitis [9].
Effects of co‑occurrence
The Eustachian tube exerts a major function in middle ear 
homeostasis via its role in the ventilation and protection 
of the middle ear and mucociliary clearance. The Eus-
tachian tube contains an allergic inflammatory infiltrate in 
AR patients [72]. It is therefore not surprising that aller-
gic inflammation with concomitant mucosal swelling may 
impair the function of the Eustachian tube [73].
Concomitant occurrence of allergic diseases and pri-
mary immune deficiencies was reported by Klemola 
[74]. Klemola [74] reported that 50% of the children with 
atopic disease had selective IgA deficiency (sIgAD). In 
allergic diseases such as asthma, atopic dermatitis, aller-
gic rhinitis, and conjunctivitis, there is predisposition 
to infections resulting from an immunodeficiency [75]. 
Immune deficiencies and infections may contribute to 
the development of OME.
Treatment
Because of the pathophysiological associations of AR with 
OME, treatments focusing on allergic inflammation may 
be helpful in the management of OME [76]. A meta-anal-
ysis of 16 randomized controlled trials demonstrated no 
significant benefit from antihistamines, decongestants, 
or combined antihistamines and decongestants versus 
placebo for treatment of OME [77]. Intranasal corticos-
teroids did reduce the need for surgery in a double blind 
study in which autoinflation of the middle ear was also 
effective, but the combination of the two was less effica-
cious [78].
Atopic status and nasal disease should be evaluated 
in recurrent or chronic OME patients who have had no 
response to antibiotic therapy, and INS could be used as an 
adjunct to treatment of some OME patients. Further stud-
ies are needed to elucidate whether atopic status or rhini-
tis itself may influence the development of OME and the 
extent of ear involvement in various forms of rhinosinusitis.
Adenoid hypertrophy (AH)
The adenoid tissue is a peripheral lymphoid organ 
located in the nasopharynx, forming part of Waldeyer’s 
ring. It contributes to the development of immunity 
against inhaled micro-organisms in early life. The vol-
ume of the adenoid increases with age and is maximal at 
5–6  years, followed by a gradual decrease in volume by 
the age of 8–9  years [79]. Symptoms related to AH are 
nasal obstruction, open mouth breathing and snoring. 
‘Adenoid face’ can be caused by AH or by severe obstruc-
tive rhinitis [61].
Extent of co‑occurrence
Children with AR appear to have a greater susceptibil-
ity to AH than non-allergic children, with IgE-mediated 
inflammation of the nasal mucosa likely playing a role in 
both conditions [80].
Adenoid hypertrophy in adults is rare and may indi-
cate underlying malignancy or infection, such as human 
immune deficiency virus (HIV), rather than allergy.
Treatment
Treatment of AR with intranasal corticosteroids has been 
shown to improve various parameters associated with 
adenoid hypertrophy [81].
Olfactory dysfunction
Extent of co‑occurrence
In a recent study of 51 subjects with AR, half had hypos-
mia [82]. Half of AR subjects with a normal CT scored 
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in the 30th percentile in an olfactory test. The degree 
of olfactory dysfunction does not seem to be related to 
the degree of nasal obstruction/nasal resistance [82], 
although with perennial (persistent) AR, the olfactory 
dysfunction seems to be more stable and more persistent 
throughout the year [83].
Reduced olfaction is more common in chronic rhinosi-
nusitis, especially when NPs are present [9].
Effects of co‑occurrence
AR may have a negative impact on olfactory function 
and is considered to be a sinonasal-related origin of che-
mosensory dysfunction [84]. This is probably secondary 
to a local inflammation in the nasal fossa and around the 
olfactory neuroepithelium in the olfactory cleft rather 
than a nasal obstruction impairing the odours to reach 
the olfactory cleft [82].
Olfactory function is a global perception of orthonasal 
and retronasal stimuli and of a stimulation of intrana-
sal trigeminal nerve endings. The trigeminal function is 
enhanced in patients with AR and a link exists between 
chemosensory trigeminal function and neuroinflamma-
tion [85]. Antidromic activation of the trigeminal nerve 
after allergen and/or chemosensory stimuli leads to the 
liberation of neuropeptides and classical trigeminal 
related symptoms such as sneezing and itching.
Treatment
Systemic corticosteroid is the first-line-treatment for 
olfactory dysfunction of sinonasal origin but use must be 
short term because of side-effects. Topical corticosteroid 
does not reach the same efficacy but has a good safety 
profile [86]. Nasal corticosteroids have a positive impact 
on AR-related olfactory dysfunction [87]. However, most 
studies have used a visual analogue scale to evaluate 
olfactory function, which is known to be a poor tool in 
comparison with other test modalities such as threshold, 
discrimination or identification tasks in olfactory testing.
Antihistamines also have a positive effect on the olfac-
tory function even if prescribed for a short period of time 
[88]. Olfactory dysfunction has marked effects on quality of 
life when severe and needs to be taken into account in the 
evaluation of comorbidities related to the presence of AR.
Laryngitis, cough and vocal problems
Effects of co‑occurrence
The passage of mediators, cytokines and secretions back-
wards from the nose should not reach the larynx, unless 
epiglottic function is disturbed. However, many patients 
with AR do experience throat symptoms, including irrita-
tion, the sensation of difficult to shift mucus and cough 
[89]. In a recent study on AR and laryngeal symptoms, 
involving six controls and six adult singers, nasal provo-
cation with pollen extracts caused a rapid induction of 
laryngeal irritation and globus sensation. However, no 
objective changes occurred then, nor during the pollen 
season [90].
Treatment
Edema of the laryngeal mucosa, laryngeal erythema and 
candidiasis may all be found in a minority of patients 
treated with inhaled glucocorticosteroids [91], but are 
not reported after the prolonged use of a nasal steroid 
spray.
Gastro esophageal reflux (GER)
Gastro esophageal reflux (GER) may masquerade as CRS 
[92]. Associations have been reported between GER and 
a variety of upper and lower respiratory tract conditions 
but not with AR [73].
Obstructive sleep apnea (OSA) and sleep impairment
The effect of AR on sleep can impair quality of life [93]. 
Patients with AR have more difficulties in falling asleep, 
take more sleeping drugs, suffer from nocturnal awaken-
ings, and feel that they do not get sufficient sleep when 
compared to healthy controls [94].
Treatment
One study [93] has demonstrated an improvement in OSA 
in a short-term trial of intranasal fluticasone propionate. 
The mixed/obstructive apnea-hypopnea index decreased 
by 4.9 ± 1.0 events per hour in the fluticasone propion-
ate group and increased by 2.2 ± 3.3 events per hour in 
the placebo group [94]. Craig et al. studied a group of 20 
adults with perennial rhinitis and sleep complaints, exam-
ining the benefit of twice-daily nasal flunisolide using a 
double-blind, placebo-controlled, crossover study. They 
found that nasal congestion and subjective sleep improved 
significantly in the topical corticosteroid-treated subjects. 
They concluded that the fatigue in perennial allergies may 
be a result of nasal congestion and associated sleep frag-
mentation. Decreasing nasal congestion with nasal ster-
oids may improve sleep, daytime fatigue, and the quality 
of life of patients with AR [95].
Fatigue and learning impairment
Extent of co‑occurrence
Patients with AR frequently complain of disordered 
sleep, daytime somnolence and inability to concentrate. 
Recent studies document daytime somnolence in chil-
dren with AR. Craig et  al. [95] reported an association 
between daytime somnolence and nasal congestion in 
a group of patients with AR. If nasal symptoms such as 
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itching, sneezing, rhinorrhea, and congestion are not well 
controlled during the day, they may contribute to learn-
ing problems during school hours. If these symptoms are 
not well controlled during the night, they may contribute 
to nocturnal sleep loss, secondary daytime fatigue and 
learning impairment [96].
Effects of co‑occurrence
Baraniuk et  al. [97], in a study of chronic fatigue syn-
drome, failed to document an increase in AR in these 
patients. However, patients with AR (unlike the group 
with rheumatologic disease) had significantly increased 
symptoms of fatigue intermediate between levels of 
Table 2 Diagnosis of multi‑morbidities associated with allergic rhinitis (AR)
Multi-morbidities of AR Definitive medical history, symptoms and signs
Asthma Ask about any history of cough, wheeze, shortness of breath, exercise-induced bronchospasm
Examine the chest for wheeze, hyperexpansion
Assess peak expiratory flows and spirometry in older children preferably with reversibility testing with beta-2 agonists
If in doubt, undertake an exercise, mannitol or methacholine challenge test or measure exhaled nitric oxide (FENO)
Conjunctivitis Ask about a history of red, itchy, watery eyes, eye rubbing
Examine eyes
Rhinosinusitis Ask about a history of nasal obstruction or discharge (purulent) with or without hyposmia, headache, facial pain or cough
Undertake nasendoscopy in older children
CT scan/sinus X-rays not recommended unless there are complications or failed therapy, unilateral symptoms or severe 
disease unresponsive to medical therapy
Otitis media with effusion 
(OME)/impaired hearing
Ask questions related to immune deficiency and/or recurrent infections
Ask about any speech and language delay, increasing volume of TV, shouting, poor concentration, failing performance at 
school, frustration, irritability
Examine the ears using a pneumatic otoscope if possible, and Weber and Rinne tests
Use tympanoscopy for evaluation of tympanic membrane and middle ear
Undertake tympanometry
Use a whisper test to screen otitis media with effusion and hearing loss
Use audiometry in older children—pure tones, speech
Obstructive sleep apnea 
and sleep problems
Enquire about any history of disturbed sleep, snoring, apnoea, tiredness, irritability
Assess nasal airway using spatula misting, nasal inspiratory peak flow, visual examination of nostrils and nasendoscopy in older 
children to view nasal airway and adenoids
Consider sleep study
Atopic dermatitis Ask about skin symptoms of itching, redness, rash
Food allergy Ask about symptoms related to food intake
Ask for oral allergy syndrome (OAS): Allergic reaction that occurs upon contact of the mouth and throat with raw fruits or 
vegetables which may be tolerated when cooked
Eosinophilic oesophagitis Ask for symptoms related to esophageal dysfunction as solid food dysphagia, chest pain, heartburn and upper abdominal 
pain
Assess esophageal biopsies
Adenoid hypertrophy Ask about nasal obstruction, open mouth breathing and snoring
Examine the face
Perform posterior rhinoscopy; nasal and nasopharyngeal rigid/flexible endoscopy
Olfactory dysfunction Ask for olfactory dysfunction, hyposmia, anosmia
Evaluate nasal airway and smell function tests
Laryngitis, cough and 
vocal problems
Ask for symptoms including irritation in the throat, the sensation of difficult to shift mucus and cough
Examine throat and larynx, see vocal cords and arytenoids
Gastro esophageal reflux Ask for symptoms of indigestion, regurgitation, cough
Examine throat and larynx
Fatigue and learning 
impairment
Ask about fatigue and learning impairment, school success
Ask about sleep quality, nasal obstruction and nasal discharge
Turbinate hypertrophy Ask about nasal obstruction
Perform anterior rhinoscopy and nasal endoscopy, acoustic rhinometry pre and post decongestant shows whether 
mucosal lining or bony structure is responsible
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fatigue seen in normal subjects and patients with chronic 
fatigue syndrome.
AR can reduce driving performance [98]. It can also 
impair examination performance in adolescents [99].
Treatment
In a study involving major examinations, sedating anti-
histamines increased the likelihood of dropping an exam-
ination grade [99]. The medications used to treat allergic 
rhinitis may cause central nervous system adverse effects 
and contribute to learning impairment. The newer rela-
tively nonsedating medications such as loratadine, ceti-
rizine, and fexofenadine have less potential to impair 
central nervous system function and learning than their 
predecessors [96].
Turbinate hypertrophy
Extent of co‑occurrence
In AR patients, nasal obstruction is a bothersome symp-
tom which is most commonly due to inferior turbinate 
hypertrophy. The inferior turbinate is the initial deposit 
point for allergens and undergoes dynamic changes 
through the allergic cascade, which results in nasal 
obstruction. Targeting the inferior turbinate to augment 
the nasal airway is the mainstay of surgical treatment in 
AR [100].
Effects of co‑occurence
The turbinates are tiny shelf-like bony structures that 
project into the nasal passageways. They help warm, 
humidify, and clean the air that passes over them. If tur-
binate hypertrophy develops, it causes persistent nasal 
congestion and, sometimes, pressure and headache in 
the middle of the face and forehead. This condition may 
require surgery [101].
Treatment
Turbinate hypertrophy which is multimorbidity of the AR 
is primarily treated by allergen avoidance and medical 
treatment, but when these measures fail to control symp-
toms then surgery to the inferior turbinates of nose can 
be performed [102]. Outfracture, submucous resection, 
laser vaporization, radiofrequency ablation, and cobla-
tion, cryosurgery, submucous electrocautery, and micro-
debriber turbinoplasty are treatment options in turbinate 
hypertrophy related to AR [103].
Fig. 1 Treatment for AR (taken from ARIA 2012) [104]. In addition to the pathways presented in the figure allergen and irritant avoidance may be 
appropriate; for conjunctivitis, add an oral H1-blocker, intraocular H1-blocker or intraocular cromone (or saline); consider specific immunotherapy 
when pharmacotherapy fails or is unacceptable to the patient
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Diagnosis
Diagnosis of multi-morbidities of AR are shown in 
Table 2 [3].
A physical examination of all organ systems potentially 
affected by allergies, with emphasis on the upper respira-
tory tract, should be performed in patients with a history 
of rhinitis.
Treatment
During the treatment of AR, multi-morbidities (co-mor-
bidities) of AR should be considered. Treatment of AR 
according to guidelines may cause decreasing the nasal 
symptoms; and may cause improvement of the co-mor-
bid problems; see Fig. 1 [104].
Conclusion
This EAACI Task Force Report on AR Multi-morbidities 
has defined and classified the multi-morbidities associ-
ated with AR, together with providing recommendations 
for diagnosis and treatment. The information provided 
here should help improve allergists’ knowledge and skills, 
ultimately improving the overall quality of patient care, as 
well as helping to raise the profile of this important area 
of work.
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